» Articles » PMID: 33156489

Drug Use Disorder and Risk of Incident and Fatal Breast Cancer: a Nationwide Epidemiological Study

Overview
Specialty Oncology
Date 2020 Nov 6
PMID 33156489
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Breast cancer is one of the most common cancer forms in women and it is often detected by screening. However, women with drug use disorders (DUD) are less likely to be reached by screening programs. In this study, we aimed to investigate breast cancer incidence, mortality and stage at time of diagnosis among women with DUD compared to the general female population in Sweden.

Methods: We performed a follow-up study based on Swedish national register data for the period January 1997-December 2015. The study was based on 3,838,248 women aged 15-75 years, of whom 50,858 were registered with DUD. Adjusted hazard ratios (HRs) for incident and fatal breast cancer, and cancer stage at time of diagnosis, were calculated for women with and without DUD using Cox regression analysis.

Results: DUD was associated with incident breast cancer (HR 1.08, 95% confidence interval [CI] 1.02-1.14, p = 0.0069), fatal breast cancer (HR 1.60, 95% CI 1.42-1.82, p < 0.001), and stage IV breast cancer, i.e. metastasis at diagnosis (HR 2.06, 95% CI 1.44-2.95, p < 0.001).

Conclusions: Women with DUD were identified as a risk group for incident, fatal and metastasized breast cancer, which calls for attention from clinicians and policy makers. Cancer screening attendance and other healthcare seeking barriers are likely to affect the risk increase among women who use drugs; however, more research is needed on the underlying mechanisms.

Citing Articles

Breast and cervical cancer in transgender men: literature review and a case report.

Di Lisa F, Villa A, Filomeno L, Arcuri T, Chiofalo B, Sanguineti G Ther Adv Med Oncol. 2024; 16:17588359241259466.

PMID: 39131728 PMC: 11316962. DOI: 10.1177/17588359241259466.


Barriers to and facilitators of screening for cervical and breast cancer: Experiences of non-adherent women with current or previous drug use.

Garpenhag L, Dahlman D Prev Med Rep. 2024; 39:102641.

PMID: 38370982 PMC: 10869932. DOI: 10.1016/j.pmedr.2024.102641.


Investigating the Link between Early Life and Breast Anomalies.

Christopoulos P, Matsas A, Eleftheriades M, Kotsira G, Eleftheriades A, Vlahos N Children (Basel). 2023; 10(3).

PMID: 36980159 PMC: 10047184. DOI: 10.3390/children10030601.


Participation in screening for breast and cervical cancer among women with current or previous drug use: a survey study.

Garpenhag L, Dahlman D BMC Public Health. 2023; 23(1):352.

PMID: 36797737 PMC: 9936631. DOI: 10.1186/s12889-023-15236-3.


Screening for breast and cervical cancer among OST patients: a qualitative study of barriers and suggested interventions to increase participation.

Garpenhag L, Dahlman D Int J Qual Stud Health Well-being. 2023; 18(1):2175767.

PMID: 36756664 PMC: 9930823. DOI: 10.1080/17482631.2023.2175767.


References
1.
Miller-Lloyd L, Landry J, Macmadu A, Allard I, Waxman M . Barriers to Healthcare for People Who Inject Drugs: A Survey at a Syringe Exchange Program. Subst Use Misuse. 2020; 55(6):896-899. DOI: 10.1080/10826084.2019.1710207. View

2.
Troberg K, Hakansson A, Dahlman D . Self-Rated Physical Health and Unmet Healthcare Needs among Swedish Patients in Opioid Substitution Treatment. J Addict. 2019; 2019:7942145. PMC: 6500657. DOI: 10.1155/2019/7942145. View

3.
Reece A . Lifetime prevalence of cervical neoplasia in addicted and medical patients. Aust N Z J Obstet Gynaecol. 2007; 47(5):419-23. DOI: 10.1111/j.1479-828X.2007.00769.x. View

4.
Ohlin L, Fridell M, Nyhlen A . Buprenorphine maintenance program with contracted work/education and low tolerance for non-prescribed drug use: a cohort study of outcome for women and men after seven years. BMC Psychiatry. 2015; 15:56. PMC: 4410480. DOI: 10.1186/s12888-015-0415-z. View

5.
Spithoff S, Kiran T, Khuu W, Kahan M, Guan Q, Tadrous M . Quality of primary care among individuals receiving treatment for opioid use disorder. Can Fam Physician. 2019; 65(5):343-351. PMC: 6516690. View